The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods. Ceftazidime had MIC 90 s of 8 g/ml and 32 g/ml in the presence and absence of NXL104, respectively. Of 25 multidrug-resistant P. aeruginosa isolates, the percentages with a ceftazidime MIC of <8 g/ml with and without NXL104 were 60% and 4%, respectively. These data suggest that the ceftazidime-NXL104 combination may prove useful for treating many P. aeruginosa infections.
Pseudomonas aeruginosa is an important cause of nosocomial respiratory, urinary tract, bloodstream, and wound infections (2, 7, 8, 11) . In recent years, P. aeruginosa clinical isolates resistant to multiple classes of antimicrobial agents have become increasingly common (9, 14) . The treatment of serious infections caused by these resistant isolates poses a therapeutic challenge for clinicians, who are often faced with extremely limited antimicrobial options from which to choose. Not surprisingly, multidrug resistance among P. aeruginosa has been associated with adverse clinical outcomes, including increased mortality (1, 10, 19) . Of concern, there are few new antimicrobial agents currently under development that have significant activity versus P. aeruginosa (4) . NXL104 (formerly AVE1330A) is a novel non-␤-lactam ␤-lactamase inhibitor currently in clinical development (17, 18) . This agent demonstrates a broad spectrum of inhibitory activity in vitro versus Ambler class A and class C ␤-lactamase enzymes (3, 13, 18) . Resistance to ␤-lactam antimicrobials among P. aeruginosa isolates is mediated, in part, by production of an AmpC enzyme (an Ambler class C ␤-lactamase) (9) . In theory, combination of NXL104 with an antipseudomonal ␤-lactam antimicrobial such as ceftazidime may result in improved activity of the corresponding ␤-lactam versus P. aeruginosa. The purpose of this study was to evaluate the in vitro activity of ceftazidime in combination with NXL104 in comparison with that of other antipseudomonal antimicrobials against P. aeruginosa clinical isolates obtained from patients in Canadian hospitals.
Fifteen tertiary-care medical centers representing 8 of the 10 Canadian provinces submitted pathogens obtained from patients attending hospital clinics, emergency rooms, medical and surgical wards, and intensive care units (CANWARD 2009 study). The sites were geographically distributed in a population-based fashion. From January through December 2009, inclusive, each study site was asked to submit clinical isolates (consecutive, one per patient, per infection site) obtained from inpatients and outpatients with bloodstream (n ϭ 165), respiratory (n ϭ 100), urine (n ϭ 50), and wound (n ϭ 50) infections. The medical centers submitted clinically significant isolates, as defined by their local site criteria. Isolate identification was performed by the submitting site and confirmed at the reference site as required (i.e., when morphological characteristics and antimicrobial susceptibility patterns did not fit the reported identification). Isolates were shipped on Amies semisolid transport media to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada), subcultured onto appropriate media, and stocked in skim milk at Ϫ80°C until MIC testing was carried out.
Following two subcultures from frozen stock, the in vitro activity of commonly used antipseudomonal antimicrobials was determined by broth microdilution, in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines (5, 6). NXL104 was obtained from Novexel, France (now owned by AstraZeneca, United Kingdom). A fixed concentration of 4 g/ml NXL104 was evaluated in combination with doubling concentrations of ceftazidime. Ten randomly selected ceftazidime-susceptible P. aeruginosa isolates were also evaluated versus doubling concentrations of NXL104 in the absence of ceftazidime. Antimicrobial MIC interpretive standards were defined according to CLSI breakpoints (6) . For doripenem, breakpoints defined by the U.S. Food and Drug Administration (FDA) were used (15) . At present, no breakpoints have been set for the combination of NXL104 and ceftazidime. Multidrug-resistant (MDR) P. aeruginosa isolates were defined as isolates demonstrating resistance to at least one antimicrobial agent from three or more different classes. For the purpose of this report, the antimicrobial classes considered were aminoglycosides (amikacin and gentamicin), fluoroquinolones (ciprofloxacin and levofloxacin), cefepime or piperacillin-tazobactam (considered together), and carbapenems (mero-penem). Colistin (polymyxin E) was not used in the classification of MDR isolates.
In (Fig. 1) . The percentages of P. aeruginosa isolates with a ceftazidime MIC of Յ8 g/ml (CLSI ceftazidime susceptibility breakpoint) with and without NXL104 were 94.3% (443/470 isolates) and 82.1% (386/470 isolates), respectively. Of 10 ceftazidime-susceptible P. aeruginosa isolates tested versus NXL104 in the absence of ceftazidime, all had an NXL104 MIC of Ն32 g/ml, indicating the lack of intrinsic antipseudomonal activity inherent to this compound.
Twenty-five P. aeruginosa isolates (5.3%) were MDR. The activity of ceftazidime in combination with NXL104 versus P. a S ϭ susceptible, I ϭ intermediate, R ϭ resistant. Breakpoint interpretation: amikacin S Յ 16 g/ml, I ϭ 32 g/ml, R Ն 64 g/ml; cefepime S Յ 8 g/ml, I ϭ 16 g/ml, R Ն 32 g/ml; ceftazidime S Յ 8 g/ml, I ϭ 16 g/ml, R Ն 32 g/ml; ciprofloxacin S Յ 1 g/ml, I ϭ 2 g/ml, R Ն 4 g/ml; colistin S Յ 2 g/ml, I ϭ 4 g/ml, R Ն 8 g/ml; doripenem S Յ 2 g/ml (FDA defined); gentamicin S Յ 4 g/ml, I ϭ 8 g/ml, R Ն 16 g/ml; levofloxacin S Յ 2 g/ml, I ϭ 4 g/ml, R Ն 8 g/ml; meropenem S Յ 4 g/ml, I ϭ 8 g/ml, R Ն 16 g/ml; piperacillin-tazobactam S Յ 64/4 g/ml, R Ն 128/4 g/ml. ND ϭ breakpoints not defined; NA ϭ not applicable, no breakpoints defined for intermediate susceptibility. Table 2 .
The percentages of MDR isolates with a ceftazidime MIC of Յ8 g/ml with and without NXL104 were 60% and 4%, respectively (Tables 1 and 2 ). To date, there have been few studies evaluating the in vitro activity of ceftazidime in combination with NXL104 versus P. aeruginosa. Mushtaq et al. investigated the in vitro activity of ceftazidime with NXL104 versus a small number of P. aeruginosa laboratory and clinical isolates (12) . When testing P. aeruginosa laboratory isolates with a fully derepressed AmpC, these investigators demonstrated a drop in the ceftazidime MIC from Ն64 g/ml to Յ8 g/ml with the addition of NXL104. Further, of 17 clinical isolates with a ceftazidime MIC of Ն8 g/ml, 11 demonstrated at least a 4-fold reduction in MIC with the addition of NXL104 (12). Sahm et al. assessed the in vitro activity of ceftazidime in combination with NXL104 versus a random selection of 300 P. aeruginosa clinical isolates collected across the United States, Europe, and Asia (16) . Addition of NXL104 to ceftazidime resulted in at least a 4-fold reduction in the ceftazidime MIC 90 (16) . These data are consistent with the results presented here.
In summary, when tested against 470 P. aeruginosa clinical isolates, addition of NXL104 to ceftazidime lowered the ceftazidime MIC by 2-to 4-fold (1 or 2 dilutions). Sixty percent of the MDR P. aeruginosa isolates evaluated had a MIC of Յ8 g/ml versus ceftazidime in combination with NXL104. These data suggest that the ceftazidime-NXL104 combination may prove useful in the treatment of many infections caused by P. aeruginosa.
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